GO:0002039 p53 binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002039 (p53 binding) is a molecular function defined as binding to one of the p53 family of proteins.
• p53 binding underlies tumor suppression by mediating protein-protein interactions that regulate p53 stability, localization, and transcriptional activity.
• The MDM2-p53 complex is a paradigm for p53 binding, where MDM2 binds the p53 transactivation domain to control p53 turnover.
• p53 binding to DNA response elements is structurally diverse, with multiple binding modes expanding the repertoire of target genes.
• Mutations in p53 that alter its DNA binding domain can also affect interactions with other proteins, contributing to oncogenic functions.
• Studying p53 binding requires integrated structural, biochemical, and CRISPR-based approaches to dissect interaction networks.
Description
The Gene Ontology (GO) term GO:0002039, p53 binding, describes a molecular function: the selective interaction of a protein with one of the p53 family proteins. This function is central to cellular regulation because p53 is a transcription factor that coordinates responses to DNA damage, oncogenic stress, and other insults. Proteins that bind p53 can modulate its stability, subcellular localization, and transcriptional output, thereby influencing cell fate decisions such as apoptosis, senescence, and DNA repair. Understanding p53 binding is therefore critical for deciphering tumor suppressor pathways and for developing therapeutic strategies that target p53 interactions. The structural basis of p53 binding has been illuminated by studies of the MDM2-p53 complex, which revealed how a small domain of p53 docks into a hydrophobic pocket on MDM2. More recent work has expanded this view by showing that p53 binding to DNA response elements occurs through diverse modes, and that p53 can also interact with nucleosomal DNA and other proteins. These findings underscore the importance of p53 binding as a hub for integrating cellular signals and maintaining genomic integrity.
p53 binding At A Glance
| GO ID | GO:0002039 |
|---|---|
| GO term | p53 binding |
| Ontology | molecular_function |
| Synonym | None |
| Definition | Binding to one of the p53 family of proteins. |
| Major function | Mediates protein-protein interactions that regulate p53 stability, localization, and transcriptional activity. |
| Related processes | DNA damage response, apoptosis, cell cycle arrest, senescence. |
| Key examples | MDM2, MDM4, Hsp90-binding immunophilins, and other p53-interacting proteins. |
| Research relevance | Target for cancer therapy and for understanding tumor suppressor pathways. |
What Is GO:0002039?
According to the QuickGO definition, GO:0002039 (p53 binding) is the molecular function of binding to one of the p53 family of proteins. This includes interactions with p53 itself as well as other family members, such as p63 and p73, although the term is primarily used for binding to p53. The function is mediated by specific structural domains and is essential for regulating p53 activity, stability, and localization.
Why Is p53 binding Important in Cell Biology?
p53 binding is important because it governs the activity of p53, a tumor suppressor that is mutated in more than half of human cancers. Proteins that bind p53 can either inhibit or enhance its function, and disrupting these interactions can lead to uncontrolled cell proliferation or therapy resistance. Moreover, p53 binding is not limited to a single partner; it encompasses a network of interactions that fine-tune p53 responses to diverse stresses. Understanding these interactions at structural and functional levels can reveal new drug targets and biomarkers for cancer and other diseases.
• Regulates p53 stability and degradation, primarily through MDM2-mediated ubiquitination.
• Controls p53 subcellular localization, including nuclear import and export.
• Modulates p53 transcriptional activity by recruiting coactivators or corepressors.
• Influences cell fate decisions such as apoptosis, senescence, and cell cycle arrest.
• Mutations in p53 that affect DNA binding can also alter protein-protein interactions, contributing to oncogenic gain-of-function.
• p53 binding to nucleosomal DNA is critical for chromatin-associated functions.
• Diverse p53/DNA binding modes expand the repertoire of p53 response elements.
• Key residues in the p53 DNA binding domain are critical for dissociation from DNA, affecting binding kinetics.
• p53 binding partners are potential therapeutic targets in cancers with wild-type p53.
• Studying p53 binding helps elucidate mechanisms of chemoresistance and radioresistance.
Molecular Mechanism of p53 binding
Structural Basis of p53 Binding to MDM2
In simple terms: MDM2 binds to a specific part of p53 to control its levels.
The crystal structure of the MDM2 oncoprotein bound to the p53 transactivation domain revealed that MDM2 uses a hydrophobic pocket to bind a short alpha-helix from p53, providing a paradigm for p53 binding. This interaction is essential for MDM2-mediated ubiquitination and degradation of p53.
p53 Binding to DNA Response Elements
In simple terms: p53 binds to DNA in different ways to turn on target genes.
p53 binds to DNA response elements through its DNA binding domain, and structural studies have shown diverse binding modes that expand the repertoire of p53 target genes. The p53 DNA binding domain can also bind to nucleosomal target DNA sequences, indicating that chromatin context influences p53 binding.
Dynamics of p53-DNA Binding
In simple terms: p53 can let go of DNA, and certain residues control this process.
Molecular dynamics simulations have elucidated dissociation pathways of the p53 DNA binding domain from DNA, highlighting critical roles of key residues in the binding interface. These findings help explain how mutations in p53 affect its DNA binding affinity and specificity.
Regulation of p53 Localization by Binding Partners
In simple terms: Some proteins help move p53 into the nucleus by binding to it.
Hsp90-binding immunophilins link p53 to dynein during p53 transport to the nucleus, demonstrating that p53 binding partners can regulate its subcellular localization. This transport mechanism is important for p53 to reach its target genes in the nucleus.
Mutant p53 and Altered Binding Properties
In simple terms: Mutant p53 can bind to different DNA elements and gain new functions.
Mutant p53 can bind to MAR-DNA elements, which may have implications for its oncogenic functions beyond loss of wild-type activity. This suggests that p53 binding is not only about wild-type function but also about how mutations redirect binding specificity.
Key Genes Involved in GO:0002039 p53 binding
The following genes and proteins are key players in p53 binding, either as p53 family members or as binding partners that regulate p53 function.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TP53 | Tumor suppressor and transcription factor; binds DNA and proteins | Central to cancer research; mutations are common in human cancers |
| MDM2 | E3 ubiquitin ligase that binds p53 and targets it for degradation | Therapeutic target; structural basis of binding is well characterized |
| MDM4 | Homolog of MDM2 that binds p53 and inhibits its activity | Regulator of p53; potential drug target |
| TP63 | p53 family member; binds DNA and proteins | Role in development and cancer; shares binding properties with p53 |
| TP73 | p53 family member; binds DNA and proteins | Involved in apoptosis and development; interacts with p53 |
| HSP90AB1 | Chaperone that binds p53 and affects its stability | Modulates p53 function; target for cancer therapy |
| DYNC1H1 | Dynein heavy chain; interacts with p53 via immunophilins | Mediates p53 nuclear transport |
| FKBP4 | Immunophilin that binds Hsp90 and p53 | Links p53 to dynein for nuclear transport |
| FKBP5 | Immunophilin that binds Hsp90 and p53 | Regulates p53 localization |
| BAX | Pro-apoptotic Bcl-2 family member; transcriptionally activated by p53 | Downstream effector of p53-mediated apoptosis |
| PUMA | Pro-apoptotic protein; binds p53 DNA binding domain | Structural basis of p53-PUMA complex elucidated |
| CDKN1A | p21; cyclin-dependent kinase inhibitor; p53 target | Mediates cell cycle arrest |
| GADD45A | Growth arrest and DNA damage-inducible protein; p53 target | Involved in DNA repair |
| MDM2 | Also binds p53 mRNA and regulates translation | Feedback loop with p53 |
| BRCA1 | Binds p53 and regulates its transcriptional activity | DNA repair and cancer susceptibility |
| CREBBP | Transcriptional coactivator that binds p53 | Enhances p53 transcriptional activity |
| EP300 | Histone acetyltransferase that binds p53 | Regulates p53 acetylation and stability |
| ATM | Kinase that phosphorylates p53 in response to DNA damage | Upstream regulator of p53 binding |
How Is p53 binding Regulated?
p53 binding is regulated at multiple levels, including post-translational modifications of p53 and its partners, and by changes in protein abundance. For example, phosphorylation of p53 by ATM and other kinases can alter its affinity for MDM2, thereby affecting degradation. Additionally, the interaction between p53 and Hsp90-binding immunophilins is regulated by the cellular stress response, influencing p53 nuclear transport. The binding of p53 to DNA is also modulated by chromatin context and the presence of specific response elements.
p53 binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TP53 | Cancer (Li-Fraumeni syndrome, sporadic tumors) | Knockout and point-mutation cell lines; xenograft models |
| MDM2 | Cancer (amplification in sarcomas, gliomas) | Overexpression and knockout models; MDM2-p53 interaction inhibitors |
| MDM4 | Cancer (amplification in melanoma, breast cancer) | Knockdown and knockout models |
| TP63 | Developmental disorders (ectodermal dysplasia) | Knock-in of patient mutations; organoid models |
| HSP90AB1 | Cancer (chaperone addiction) | Knockout and point-mutation models; Hsp90 inhibitors |
p53 Binding in Cancer
Dysregulation of p53 binding is a hallmark of many cancers. Overexpression of MDM2 or MDM4, which bind and inhibit p53, effectively inactivates p53 in tumors with wild-type TP53. Mutations in TP53 that alter its DNA binding domain can also change its interactions with proteins, leading to gain-of-function oncogenic activities. Targeting the MDM2-p53 interaction has emerged as a therapeutic strategy to reactivate p53 in tumors.
p53 Binding in Neurodegeneration
p53 binding partners are also implicated in neurodegenerative diseases, where p53 activation can contribute to neuronal death. However, direct evidence linking specific p53 binding events to neurodegeneration is still emerging, and further research is needed to establish causal roles.
p53 Binding in Developmental Disorders
p53 family members, including p63 and p73, are critical for development, and their binding interactions are essential for proper tissue morphogenesis. Mutations in TP63 that affect its binding properties can cause developmental syndromes, highlighting the importance of p53 binding in normal development.
From p53 binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate gene regulate p53 stability? | Knockout cell lines (e.g., HCT116 p53+/+) followed by p53 half-life assays |
| Does a point mutation in TP53 alter its binding to MDM2? | Point-mutation knock-in cell lines expressing mutant p53 |
| Does a protein bind p53 in vivo? | Knock-in of tagged p53 (e.g., GFP or HA) for co-immunoprecipitation |
| Does overexpression of a p53 binding partner affect apoptosis? | Overexpression cell lines and apoptosis assays |
| Does a p53 binding site mutation affect target gene activation? | Knock-in of mutant p53 response elements in reporter cell lines |
| Does a gene affect p53 nuclear transport? | Knockout of transport proteins and imaging of p53 localization |
How to Study the p53 binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| X-ray crystallography | Atomic structure of protein complexes | Determining p53-MDM2 interface |
| Cryo-EM | Structures of large complexes | p53-nucleosome complexes |
| Isothermal titration calorimetry | Binding affinity and thermodynamics | Quantifying p53-peptide interactions |
| Co-immunoprecipitation | Protein-protein interactions in cells | Validating p53 binding partners |
| Molecular dynamics simulations | Binding kinetics and pathways | Studying p53-DNA dissociation |
| CRISPR knockout | Loss-of-function phenotypes | Testing role of p53 binding partners |
| CRISPR knock-in | Precise mutation of binding sites | Modeling patient mutations |
| RNA-seq | Transcriptional changes | Identifying p53 target genes |
Structural Biology Methods
X-ray crystallography and cryo-electron microscopy have been used to determine the structures of p53 in complex with MDM2 and DNA, revealing the molecular details of binding. These methods provide atomic-level insights into the interfaces and guide the design of inhibitors.
Biochemical Binding Assays
Techniques such as isothermal titration calorimetry, surface plasmon resonance, and co-immunoprecipitation are used to measure the affinity and kinetics of p53 binding to its partners. These assays are essential for validating interactions identified by high-throughput screens.
Molecular Dynamics Simulations
Computational approaches like molecular dynamics simulations have elucidated the dissociation pathways of p53 from DNA, highlighting critical residues and providing mechanistic insights that complement experimental structures.
Genome Editing and Functional Genomics
CRISPR-Cas9 knockout, point mutation, and knock-in models allow researchers to test the functional consequences of altering p53 binding interfaces in cells. These models are combined with transcriptomics and proteomics to dissect downstream effects.
How CRISPR Can Be Used to Study GO:0002039 p53 binding
Knockout
CRISPR knockout of genes encoding p53 binding partners, such as MDM2 or immunophilins, can reveal their roles in p53 regulation. For example, MDM2 knockout leads to p53 stabilization and cell cycle arrest, demonstrating the importance of this interaction. Knockout models are also used to study the contribution of p53 binding to drug responses.
Point Mutation
Point mutations in TP53 that alter its binding properties can be introduced using CRISPR base editing or homology-directed repair. These models help dissect the specific residues required for p53 binding to MDM2 or DNA, as highlighted by structural and simulation studies.
Knock-in
Knock-in of tagged p53 or mutant response elements allows for precise tracking of p53 binding in live cells. For instance, knock-in of a GFP-tagged p53 enables imaging of p53 localization and interactions. Knock-in of mutant p53 response elements can test the effect of binding site mutations on target gene activation.
Overexpression
Overexpression of p53 binding partners, such as MDM2 or MDM4, can mimic their amplification in cancers and test their ability to inhibit p53. These models are valuable for evaluating drugs that disrupt p53 binding, such as MDM2 inhibitors.
How EDITGENE Supports p53 binding Research
Researchers studying p53 binding-related genes often need to determine whether a candidate gene is causally involved in p53 regulation or whether its interaction is merely correlative. This requires precise genetic models that can knockout, mutate, or tag the gene of interest and its binding interfaces. EDITGENE provides a comprehensive suite of CRISPR services to generate such models efficiently and reliably.
Contact EDITGENE today to design your custom CRISPR model for p53 binding research.
Frequently Asked Questions About p53 binding
What is GO:0002039 p53 binding?
GO:0002039 is a Gene Ontology molecular function term defined as binding to one of the p53 family of proteins. It encompasses protein-protein interactions that regulate p53 stability, localization, and activity.
What genes are involved in p53 binding?
Key genes include TP53 itself, MDM2, MDM4, TP63, TP73, and various chaperones and immunophilins such as HSP90AB1 and FKBP4.
How does MDM2 bind to p53?
MDM2 binds the p53 transactivation domain through a hydrophobic pocket, as revealed by the crystal structure of the complex.
What is the role of p53 binding in cancer?
p53 binding regulates tumor suppression; overexpression of MDM2 or MDM4 inhibits p53, and mutant p53 can gain oncogenic functions through altered binding.
How can I study p53 binding using CRISPR?
CRISPR knockout, point mutation, and knock-in models allow functional dissection of p53 binding interfaces and their downstream effects.
What methods are used to measure p53 binding affinity?
Isothermal titration calorimetry, surface plasmon resonance, and co-immunoprecipitation are commonly used to quantify p53 binding.
What is the structural basis of p53 binding to DNA?
p53 binds DNA response elements through its DNA binding domain, with diverse binding modes and interactions with nucleosomal DNA.
How do mutations in p53 affect its binding?
Mutations in the p53 DNA binding domain can alter DNA binding and also affect protein-protein interactions, contributing to gain-of-function.
What is the role of immunophilins in p53 binding?
Hsp90-binding immunophilins link p53 to dynein, facilitating p53 transport to the nucleus.
Why is p53 binding important for drug discovery?
Targeting p53 binding interfaces, such as the MDM2-p53 interaction, is a promising strategy to reactivate p53 in tumors with wild-type TP53.
Conclusion
GO:0002039 p53 binding is a fundamental molecular function that governs the tumor suppressor activity of p53. Through interactions with proteins like MDM2 and with DNA response elements, p53 binding controls cell fate decisions and is frequently dysregulated in cancer. Advances in structural biology, molecular dynamics, and CRISPR-based models continue to unravel the complexities of p53 binding, offering new opportunities for therapeutic intervention. Researchers can leverage EDITGENE's CRISPR services to generate precise models and accelerate discoveries in this critical field.
References
- 1. Brázda V et al.. 2019. The Rich World of p53 DNA Binding Targets: The Role of DNA Structure.. Int J Mol Sci 20(22) PMID: 31717504
- 2. Kussie PH et al.. 1996. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.. Science 274(5289):948-53 PMID: 8875929
- 3. Han CW et al.. 2021. Structural basis of the p53 DNA binding domain and PUMA complex.. Biochem Biophys Res Commun 548:39-46 PMID: 33631672
- 4. Nishimura M et al.. 2022. Structural basis for p53 binding to its nucleosomal target DNA sequence.. PNAS Nexus 1(4):pgac177 PMID: 36714865
- 5. Vyas P et al.. 2017. Diverse p53/DNA binding modes expand the repertoire of p53 response elements.. Proc Natl Acad Sci U S A 114(40):10624-10629 PMID: 28912355
- 6. Deppert W. 1996. Binding of MAR-DNA elements by mutant p53: possible implications for its oncogenic functions.. J Cell Biochem 62(2):172-80 PMID: 8844397
- 7. Sobeh MM et al.. 2022. Dissociation Pathways of the p53 DNA Binding Domain from DNA and Critical Roles of Key Residues Elucidated by dPaCS-MD/MSM.. J Chem Inf Model 62(5):1294-1307 PMID: 35234033
- 8. Galigniana MD et al.. 2004. Hsp90-binding immunophilins link p53 to dynein during p53 transport to the nucleus.. J Biol Chem 279(21):22483-9 PMID: 15004035
